|
|
||||||||
Harvard Medical School and Peter Bent Brigham Hospital, Boston, Massachusetts
Correspondence: For reprints contact: B. Leonard Holman, Dept. of Radiology, Harvard Medical School, 25 Shattuck St., Boston, Mass. 02115.
ABSTRACT
The suitability of various radiopharmaceuticals (99mTc-tetracycline analogs, 99mTc-glucoheptonate, 99mTc-disphosphonate, and 67Ga-citrate) for use in imaging acute myocardial infarction was assessed by determining their biologic distributions in experimentally infarcted dogs. The highest infarct-to-normal myocardial concentration ratio was found with 99mTc-diphosphonate (27.9:1); the highest infarct-to-liver ratio was also found with 99mTc-diphosphonate (15.9:1). The infarct-to-bone ratio, however, was 0.4:1 with 99mTc-diphosphonate. There was an excellent positive linear correlation between blood-flow reduction and uptake of the radiopharmaceutical after a threshold reduction in blood flow with 99mTc-glucoheptonate and 99mTc-tetracycline. Technetium-99m-tetracycline accumulated only in infarcted tissue while 99mTc-diphosphonate was increased in both ischemic and infarcted tissue. Thus, 99mTc-diphosphonate has characteristics best suited for scintigraphic imaging. Since 99mTc-tetracycline accumulates only in infarcted tissue, however, this tracer more accurately defines the size of an acute infarction.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |